search
alopecia areata
Trends
- 1New Rezpegaldesleukin Data Shows Durable Results at EADV 2026▼New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
New clinical data for rezpegaldesleukin, an immune-regulating drug candidate, show long-term durability and disease improvement in patients with alopecia areata and atopic dermatitis. The findings are being presented at the EADV Congress 2026, Europe's major dermatology meeting. The data support the treatment's potential for these chronic inflammatory skin conditions, where maintaining improvement over time remains a key challenge for patients and physicians.
- 2Two-Year Data for Alopecia Drug LEQSELVI Shows Sustained Efficacy▼New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026
Sun Pharmaceutical announced two-year clinical data for LEQSELVI (deuruxolitinib) in severe alopecia areata, presented at the EADV Congress 2026. The results showed sustained efficacy and a consistent safety profile in patients over the extended treatment period. The findings reinforce the drug's long-term value for people with severe hair loss, though discussion so far appears limited to the announcement itself.